Komori
Astellas Pharma (4503) · InitiativeAchieved

Discontinuation of ASP0598 Development

First written in FY2024. 1 of 1 entries say "Achieved", first in FY2024. Latest entry: FY2024.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Discontinuation of ASP0598 Development for Chronic Tympanic Membrane PerforationA theme 1 companies write about · 1 as a headwind · 0 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2024AchievedAnnual report

    「2023年８月　慢性鼓膜穿孔を対象として第Ⅰ相段階にあったASP0598の開発を中止したことを公表しました。」

    慢性鼓膜穿孔を対象とする第Ⅰ相段階のASP0598の開発中止を実施した。
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
Astellas Pharma's next results are scheduled for 2026-11-04. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Discontinuation of ASP0598 Development | Astellas Pharma Inc. (4503) | Komori